Efficacy & toxicity of CAR-T therapy in patients with secondary CNS involvement

Efficacy & toxicity of CAR-T therapy in patients with secondary CNS involvementПодробнее

Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphomaПодробнее

CAR T-cell therapy for relapsed ALL with CNS involvementПодробнее

The need to improve management and treatment strategies for secondary CNS lymphomaПодробнее

Side Effects of CAR T Cell TherapyПодробнее

Safety and efficacy of rapcabtagene autoleucel (YTB323), a CAR T-cell therapy, in r/r DLBCLПодробнее

Secondary CNS lymphoma: recent data and future approachesПодробнее

CD19 CAR-T for CNS lymphomaПодробнее

The role of CAR-T therapy in primary and secondary CNS lymphomaПодробнее

TEDDi-R regimen for secondary CNS lymphomaПодробнее

Tisa-cel in patients with primary CNS lymphomaПодробнее

CAR T-cells in Multiple MyelomaПодробнее

Updates in CAR T Cell TherapiesПодробнее

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapyПодробнее

Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cellsПодробнее

Analyzing CAR T-Cell Neurotoxicity in Adult Patients With ALLПодробнее

Real World Outcomes of CAR T Therapy – Experiences from Different ContinentsПодробнее

Managing CAR T-Cell Therapy ToxicityПодробнее

Side Effects of CAR T-cell TherapyПодробнее

Using MRD status as a metric of CAR-T efficacy in patients with multiple myelomaПодробнее